NASH Observatory 2025 - Page 19 Of 38

NASH Observatory

New insights into liver macrophages in NASH pathogenesis

Prof Tacke, Germany reviews the epidemiological challenge of NAFLD and NASH worldwide, especially with the obesity pandemic. He describes the clinical impact of inflammation and fibrosis in NAFLD and the role of macrophages. Finally, he discusses the possible therapeutic implications.

ByProf. Frank Tacke
OnMay 31, 2021

NASH Observatory Commented Articles Ppar Articles

PPARs as candidates for the treatment of NAFLD

The prevalence of NAFLD is dramatically increasing in developed countries, but no approved therapy is available. Most of the current pharmacological strategies target comorbidities, such as manifestations of metabolic syndrome. In addition, none of used medications improve fibrosis, which is the strongest indicator of mortality in NAFLD...

ByDr. G. Bozet, MD
OnMay 31, 2021

NASH Observatory Commented Articles

NAFLD is significantly related to non-achievement of LDL cholesterol targets

To reduce cardiovascular disease (CVD) risk as much as possible, current guidelines recommend optimising LDL cholesterol management based on an individual’s CVD risk level. The risk of CVD among NAFLD patients is likely to be higher than it is in...

ByDr. D. Beard
OnMay 31, 2021

NASH Observatory

Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 1

Prof. Chris Byrne (UK) discusses NAFLD as a multisystem disease and how NAFLD is a risk factor for other extra hepatic diseases beyond the liver

ByProf. Christopher Byrne
OnMay 31, 2021

NASH Observatory Commented Articles

OSA with NAFLD in patients with obesity: an observational study

A growing amount of evidence has correlated obstructive sleep apnea (OSA) with the presence of NAFLD and it has been demonstrated a direct association between the severity of the former and the progression of the latter. Thus, OSA patients should be screened for the presence and severity of NAFLD...

ByDr. G. Bozet, MD
OnMay 27, 2021

Patients with biopsy proven NAFLD: a significantly increased cancer incidence

Recent studies link NAFLD to an increased incidence of hepatocellular carcinoma (HCC) and extrahepatic cancers. However, prior studies were small or lacked liver histology, which remains the gold standard for staging NAFLD severity. TG Simon et al...

ByDr. D. Beard
OnMay 27, 2021

Management Articles Commented Articles NASH Observatory Ppar Articles

Fibrosis in NASH: targeted therapies

Progress in uncovering pathogenic determinants of fibrosis in NASH include metabolic dysregulation in hepatocytes that induce inflammation and cytokine secretion leading to cell injury and apoptosis, among others.This review by T. M. Huisman et al. (Division of Liver Diseases, Icahn School of Medicine at Mount Sinai...

ByDr. G. Bozet, MD
OnMay 25, 2021

NASH Observatory Commented Articles Epidemiology Articles

NAFLD progression rates: a real-world analysis

The aim of this study by R. Loomba et al. (NAFLD Research Center, University of California, San Diego, USA) was to evaluate the impact of disease severity, demographics and comorbidities on risk of mortality and time to progression in a large, real-world cohort of diagnosed NAFLD patients...

ByDr. D. Beard
OnMay 25, 2021

NASH Observatory

Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2

It is well known that NAFLD and T2DM occur commonly together. Prof Byrne (Southampton, UK) discusses the latest findings showing that NAFLD is an independent risk factor for cardiovascular events. The aetiology of increased risk of CVD is complex but the atherogenic dyslipidaemia is important. Genotypes can increase severity of liver disease and diabetes, yet attenuate risk of CVD.

ByProf. Christopher Byrne
OnMay 20, 2021

NASH Observatory Commented Articles

Patients with psoriasis: a screening algorithm for NAFLD

Psoriasis is an immune-mediated systemic inflammatory disease that may be associated with arthritis, cardiovascular diseases, metabolic syndrome including diabetes and obesity and as identified more recently, NAFLD, that occurs in approximately 50 % of all patients with psoriasis. In 2019, the American Academy of Dermatology...

ByDr. G. Bozet, MD
OnMay 20, 2021

NASH Observatory Commented Articles

Statin use among patients with NAFLD

Patients with NAFLD are at an increased risk of cardiovascular disease. Statins reduce the risk of cardiovascular events. Studies have shown statins are safe among patients with liver disease. Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity. This study aimed to assess prevalence...

ByDr. D. Beard
OnMay 20, 2021

NASH Observatory Commented Articles Epidemiology Articles

Adult US population: NAFLD prevalence 38%, NASH 14%

S. A. Harrison et al. (Radcliffe Department of Medicine, University of Oxford, UK) prospectively assessed the prevalence and severity of NAFLD/NASH in a cohort of asymptomatic middle-aged Americans attending a colonoscopy class at a gastroenterology clinic. Screening for NAFLD was performed using magnetic resonance...

ByDr. G. Bozet, MD
OnMay 17, 2021